Technetium Tc 99m Nofetumomab Merpentan
Technetium Tc 99m Nofetumomab Merpentan Uses, Dosage, Side Effects, Food Interaction and all others data.
Technetium Tc 99m Nofetumomab Merpentan (Tc-99m nm) consists of a Fab fragment of an IgG2b of the pancarcinoma murine antibody NR-LU-10. The NR-LU-10 antibody is directed against a 40 kDa glycoprotein antigen expressed in a variety of cancers and some normal tissues. Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992. It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.
Studies have shown that the Fab fragment presents high immunoreactivity in small cell lung cancer tumors. The adenocarcinomas of the kidney and pancreas are not detected. This lack of diagnostic detection can be explained because some radioactivity gets accumulated in the excretion pathway, in nonspecific vascular locations and in non-tumor areas with traces of inflammation, increased vascular pool or recent surgical. Therefore, the detection rate may be reduced in those areas and its adjacent zones.
| Trade Name | Technetium Tc 99m Nofetumomab Merpentan |
| Generic | Technetium Tc-99m nofetumomab merpentan |
| Technetium Tc-99m nofetumomab merpentan Other Names | Nofetumomab, Technetium (99mTc) nofetumomab merpentan, Technetium Tc 99m nofetumomab merpentan |
| Type | |
| Protein binding | There are no reports of binding of Tc-99m nm to binding proteins. |
| Groups | Approved, Withdrawn |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Tc-99m nm is one of the technetium-labeled antibodies and it is indicated for the detection of small-cell lung cancer. The small cell lung cancer is a syndrome characterized by the abnormal and uncontrolled cell growth and it is characterized by a shorter doubling time, higher growth fraction and earlier development of metastases.
How Technetium Tc 99m Nofetumomab Merpentan works
The mechanism of action in Tc-99m nm is ruled by the presence of nofetumomab, which can recognize the pancarcinoma antigen EpCAM and/or CD20/MS4A1, and merpentan, that acts as a linker for the binding of technetium.
Toxicity
Long-term preclinical studies to determine the carcinogenic, mutagenic or fertility effect have not been studied.
Elimination Route
After intravenous administration, Tc-99m nm presents a rapid distribution phase.
Half Life
The radioactive half-life of the Tc-99m nm is of 6 hours. It is important to consider this short half-life as the use of this agent should be done within the active time. Tc-99m nm presents a serum half-life of 1.5 hours and an elimination phase half-life of 10.5 hours.
Elimination Route
The primary route of elimination is renal and accounts for the 64% of the administered dose. After renal clearance, the main route is hepatobiliary. All the different elimination pathways lead to accumulation of radioactivity on the kidney, urinary bladder, gall bladder and intestines.
Innovators Monograph
You find simplified version here Technetium Tc 99m Nofetumomab Merpentan
